Followed your link and tracked down the source of that link.
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma | Cancer Research | American Association for Cancer Research (aacrjournals.org)
July 23 was the last update.
I think the ground breaking news November 15 will be based around this article. Paxalisib mentioned 88 times.
ONC201 on its own has limited success, potent in combination in a specified category.
I think its been mentioned before but FDA approval is a no brainer.
